Back to search
FDAFDA · Food and drugs·Recall number D-0723-2021

Ethosuximide Oral Solution USP 250 mg/5 mL, 16 fl oz (473 mL), Rx ONLY, Pharmaceutical Associates, Inc. Greenville, SC 29605, NDC 0121-0670-16

Published August 18, 2021 · Recall initiated: July 29, 2021

Summary

FDA records drug Class II recall D-0723-2021, published August 18, 2021 and initiated July 29, 2021. Recalling firm: PAI Holdings, LLC. dba Pharmaceutical Associates Inc; Status: Terminated; Reported quantity: 75 cases (6 bottles/case); Lot: Lot: C9BC Exp. 31OCT2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.

What to do

Voluntary: Firm initiated · Letter

Get an email if ETHOSUXIMIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
ETHOSUXIMIDE
Manufacturer
PAI Holdings, LLC. dba Pharmaceutical Associates Inc
Distributor
Distributed Nationwide in the USA
UPC
0301210670169
Lot
Lot: C9BC Exp. 31OCT2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ethosuximide Oral Solution USP 250 mg/5 mL, 16 fl oz (473 mL), Rx ONLY, Pharmaceutical Associates, Inc. Greenville, SC 29605, NDC 0121-0670-16 recalled?

Yes. FDA published recall D-0723-2021 on August 18, 2021. Reported hazard: Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: ETHOSUXIMIDE. UPC: 0301210670169.